Clinical overview of promising nonthienopyridine antiplatelet agents

American Heart Journal

Volumn 156, Issue 2 SUPPL., 2008, Pages 23S-28S

  Angiolillo, Dominick J ^a   Guzman, Luis A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARC 69931MX; CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; NITRATE; PLACEBO; PURINERGIC P2Y12 RECEPTOR; SCH 530348; TICAGRELOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ADJUVANT THERAPY; ANTICOAGULANT THERAPY; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING TIME; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INJECTION SITE REACTION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PETECHIA; PRIORITY JOURNAL; REBOUND; SECONDARY PREVENTION; SKIN BRUISING; ST SEGMENT ELEVATION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

EID: 47649113839     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.06.006     Document Type: Article

References (16)

1. Peters G., and Robie G. Single-dose pharmacokinetics and pharmacodynamics of AZD6140-an oral reversible ADP receptor antagonist. [abstract]. Haematologica 989 Suppl 7 (2004) 14
2. Husted S., Emanuelsson H., Heptinstall S., et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27 (2006) 1038-1047
3. Cannon C.P., Husted S., Harrington R.A., et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50 (2007) 1844-1851
4. Storey R.F., Husted S., Harrington R.A., et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50 (2007) 1852-1856
5. Nassim M.A., Sanderson J.B., Clarke C., et al. Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers. [abstract]. J Am Coll Cardiol 33 2 Suppl A (1999) 255A
6. Jarvis G.E., Nassim M.A., Humphries R.G., et al. The P2T antagonist AR-C69931MX is a more effective inhibitor of ADP-induced platelet aggregation than clopidogrel. Blood 94 Suppl 1 (1999) 22A
7. Greenbaum A.B., Ohman E.M., Gibson M.S., et al. Intravenous adenosine diphosphate P2T platelet receptor antagonism as an adjunct to fibrinolysis for acute myocardial infarction. J Am Coll Cardiol 39 Suppl (2002) 281A
8. Storey R.F., Oldroyd K.G., and Wilcox R.G. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85 (2001) 401-407
9. Jacobsson F., Swahn E., Wallentin L., et al. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 24 (2002) 752-765
10. Storey R.F., Wilcox R.G., and Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 13 (2002) 407-413
11. Greenbaum A.B., Grines C.L., Bittl J.A., et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 151 (2006) 689.e1-689.e10
12. Angiolillo D.J., Fernandez-Ortix A., Bernanrdo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
13. Angiolillo D.J. ADP receptor antagonism: what's in the pipeline?. Am J Cardiovasc Drugs 7 (2007) 423-432
14. Steinhubl S.R., Oh J.J., Oestreich J.H., et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121 (2008) 527-534
15. Kosoglou T., Larisa Reyderman L., Robert R., et al. Pharmacodynamics and pharmacokinetics of a novel protease-activated receptor (PAR-1) antagonist SCH 530348. [abstract]. Circulation 112 Suppl (2005) 1-32
16. Moliterno D.J., Becker R.C., Jennings L.K., et al. Results of a multinational randomized double-blind, placebo-controlled study of a novel thrombin receptor antagonist in percutaneous coronary intervention. Presented at the Late Breaking Clinical Trials at the American College of Cardiology Scientific Sessions, New Orleans, Louisiana, March 24-27 (2007)